PGGM Investments decreased its holdings in argenex SE (NASDAQ:ARGX – Free Report) by 28.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,830 shares of the company’s stock after selling 21,869 shares during the quarter. PGGM Investments’ holdings in argenex were worth $46,109,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ARGX. Abound Wealth Management grew its holdings in argenex by 3,200.0% in the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after buying an additional 32 shares during the period. Sound Income Strategies LLC purchased a new stake in argenex in the 4th quarter valued at about $28,000. Ameriflex Group Inc. purchased a new stake in argenex in the 3rd quarter valued at about $32,000. Sunbelt Securities Inc. purchased a new stake in argenex in the 3rd quarter valued at about $36,000. Finally, Aventura Private Wealth LLC purchased a new stake in argenex in the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.
Analysts Set New Price Targets
Several research firms have commented on ARGX. Guggenheim lifted their price target on argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a report on Friday, May 8th. Oppenheimer reduced their price objective on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research note on Thursday, April 2nd. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Royal Bank Of Canada reduced their price objective on argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research note on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research note on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,017.78.
argenex Price Performance
NASDAQ ARGX opened at $806.46 on Tuesday. The firm has a market capitalization of $49.90 billion, a P/E ratio of 35.91, a P/E/G ratio of 1.28 and a beta of 0.46. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The business’s 50-day simple moving average is $769.12 and its 200-day simple moving average is $815.62.
argenex (NASDAQ:ARGX – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The business had revenue of $1.31 billion for the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. On average, equities research analysts expect that argenex SE will post 25.27 EPS for the current fiscal year.
argenex Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
Featured Articles
- Five stocks we like better than argenex
- SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns
- Microsoft Stock Discount May Be Ending as AI Catalysts Build
- Apparel Earnings Winners and Losers: Ralph Lauren Takes Off
- Why Walmart, Target and TJX Got Such Different Reactions After Earnings
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX – Free Report).
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
